Methylation of cytochrome p450 2E1 promoter induced by low dosage of isoniazid

Environmental Toxicology and Pharmacology

Volumn 36, Issue 1, 2013, Pages 149-151

  Shen, Lihong ^a,b   Zhang, Bing ^c   Sun, Shufeng ^b   Feng, Fumin ^b  

^a State Key Laboratory of Media Convergence Production Technology and Systems   (China)

^b HEBEI UNITED UNIVERSITY   (China)

^c TANGSHAN PEOPLE S HOSPITAL   (China)

Author keywords

Isoniazid; Liver injury; Methylation

Indexed keywords

CYTOCHROME P450 2E1; ISONIAZID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SWELLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HISTOPATHOLOGY; LIVER CELL; LIVER INJURY; LOW DRUG DOSE; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; RAT;

ANIMALS; ANTITUBERCULAR AGENTS; CYTOCHROME P-450 CYP2E1; DNA METHYLATION; ISONIAZID; LIVER; MALE; PROMOTER REGIONS, GENETIC; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84876727675     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2013.03.016     Document Type: Article

References (10)

1. Centers for Disease Control and Prevention (CDC) Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. MMWR Morb. Mortal. Wkly. Rep. 2010, 59(8):224-225.
2. de Souza C.T., Hokerberg Y.H., Pacheco S.J., Rolla V.C., Passos S.R. Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro. Mem. Inst. Oswaldo Cruz 2009, 104:462-467.
3. Gomez A., Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin. Pharmacol. Ther. 2009, 85:426-430.
4. Han D., Shinohara M., Ybanez M.D., Saberi B., Kaplowitz N. Signal transduction pathways involved in drug-induced liver injury. Handb. Exp. Pharmacol. 2010, 196:267-310.
5. Helmig S., Dohrel J., Schneider J. Decreased Cytochrome p4502E1 mRNA expression in human leucocytes in patients with fibrotic and inflammatory lung diseases. Int. J. Mol. Med. 2010, 26(1):143-149.
6. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(18):9821-9826.
7. Kovalenko V.M., Bagnyukova T.V., Sergienko O.V., Bondarenko L.B., Shayakhmetova G.M., Matvienko A.V., Pogribny I.P. Epigenetic changes in the rat livers induced by pyrazinamide treatment. Toxicol. Appl. Pharmacol. 2007, 225:293-299.
8. Saghir S.A., Zhang F., Rick D.L., Kan L., Bus J.S., Bartels M.J. In vitro metabolism and covalent binding of ethylbenzene to microsomal protein as a possible mechanism of ethylbenzene-induced mouse lung tumorigenesis. Regul. Toxicol. Pharmacol. 2010, 57(2-3):129-135.
9. Takahashi H., Ogata H., Nishigaki R., Broide D.H., Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKK[beta]-and JNK1-dependent inflammation. Cancer Cell 2010, 17(1):89-97.
10. Tostmann A., Boeree M.J., Aarnoutse R.E., de Lange W.C., van der Ven A.J., Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 2008, 23:192-202.